Skip to main content

89bio, Inc. (ETNB)

NASDAQ: ETNB · IEX Real-Time Price · USD
17.50 0.11 (0.63%)
Oct 21, 2021 4:00 PM EDT - Market closed
Market Cap349.33M
Revenue (ttm)n/a
Net Income (ttm)-62.69M
Shares Out20.06M
EPS (ttm)-3.27
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume32,355
Open17.46
Previous Close17.39
Day's Range17.40 - 17.78
52-Week Range14.70 - 28.28
Betan/a
AnalystsStrong Buy
Price Target52.00 (+197.1%)
Est. Earnings DateNov 9, 2021

About ETNB

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.

IndustryBiotechnology
IPO DateNov 11, 2019
Employees26
Stock ExchangeNASDAQ
Ticker SymbolETNB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for 89bio stock is "Strong Buy." The 12-month stock price forecast is 52.00, which is an increase of 197.14% from the latest price.

Price Target
$52.00
(197.14% upside)
Analyst Consensus: Strong Buy

News

89bio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

SAN FRANCISCO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the ...

1 month ago - GlobeNewsWire

89bio to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the t...

2 months ago - GlobeNewsWire

89bio Completed Target Enrollment in Histology Cohort to Evaluate BIO89-100 for the Treatment of NASH

- Study designed to build upon positive Phase 1b/2a data and provide an early opportunity to demonstrate BIO89-100's potential benefits on histology endpoints - - Study designed to build upon positive P...

2 months ago - GlobeNewsWire

89bio Reports First Quarter 2021 Financial Results and Provides Corporate Update

ENLIVEN Phase 2b trial in NASH expected to be initiated in 2Q21 ENLIVEN Phase 2b trial in NASH expected to be initiated in 2Q21

5 months ago - GlobeNewsWire

89bio to Present at Upcoming Investor Conferences

SAN FRANCISCO, May 05, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the tr...

5 months ago - GlobeNewsWire

89bio Announces Plans for Phase 2b (ENLIVEN) Trial in NASH

- Received written guidance from FDA related to trial design and agreement to use liquid formulation - - ENLIVEN trial to initiate as planned in 2Q21 -

6 months ago - GlobeNewsWire

89bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

- Initiation of BIO89-100 Phase 2b NASH trial planned in 1H21 -

6 months ago - GlobeNewsWire

89bio Presents Additional Analysis of Phase 1b/2a NASH Study at the Annual ENDO 2021 Conference

New analysis shows BIO89-100 meaningfully reduces liver fat volume and liver volume in patients with NASH New analysis shows BIO89-100 meaningfully reduces liver fat volume and liver volume in patients ...

7 months ago - GlobeNewsWire

89bio to Present at the Oppenheimer 31st Annual Healthcare Conference

SAN FRANCISCO, March 11, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the ...

7 months ago - GlobeNewsWire

89bio to Present at the 42nd Annual Raymond James Institutional Investors Conference

SAN FRANCISCO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the t...

7 months ago - GlobeNewsWire

89bio: NASH Drug Developer With Differentiated Profile

BIO89-100 is lead and only molecule targeting NASH with superior early-stage data. Among its peer group, molecule is well differentiated.

8 months ago - Seeking Alpha

89bio to Participate in the H.C. Wainwright BioConnect 2021 Conference

SAN FRANCISCO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the t...

9 months ago - GlobeNewsWire

89bio To Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

SAN FRANCISCO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the t...

10 months ago - GlobeNewsWire

89bio Presents Updated Clinical Data from Positive Phase 1b/2a Study of BIO89-100 in NASH at AASLD's The Liver Meetin...

– Data demonstrated compelling efficacy profile and favorable tolerability with weekly and every two-week dosing –

11 months ago - GlobeNewsWire

89bio Reports Third Quarter 2020 Financial Results and Provides Corporate Update

– Updated clinical data from BIO89-100 's Phase 1b/2a NASH trial to be presented as a late-breaking poster at upcoming AASLD Liver Meeting –

11 months ago - GlobeNewsWire

89bio to Present at Upcoming Investor Conference

SAN FRANCISCO, Sept. 28, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for th...

1 year ago - GlobeNewsWire

89bio Announces Pricing of Upsized Public Offering of Common Stock

SAN FRANCISCO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for th...

1 year ago - GlobeNewsWire

89bio Announces Proposed Public Offering of Common Stock

SAN FRANCISCO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for th...

1 year ago - GlobeNewsWire

89bio Announces Positive Topline Results from its Phase 1b/2a Trial of BIO89-100 in NASH

All dose groups achieved statistically significant reductions in liver fat, with relative reductions of up to 60% versus baseline and up to 70% versus placebo    

1 year ago - GlobeNewsWire

89bio to Announce Topline Results from Phase 1b/2a Study of BIO89-100 in NASH

SAN FRANCISCO, Sept. 13, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB) today announced that the company plans to share topline safety, tolerability and efficacy data from its Phase 1b/2a study o...

1 year ago - GlobeNewsWire

89bio Initiates Phase 2 Trial of BIO89-100 in Patients with Severe Hypertriglyceridemia

- Multi-center, randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of BIO89-100 administered weekly or every two weeks for 8 weeks - - Multi-center, randomized, dou...

1 year ago - GlobeNewsWire

89bio Reports Second Quarter 2020 Financial Results and Provides Corporate Update

- Topline results from BIO89-100’s Phase 1b/2a NASH trial are expected in Late Q3 to Early Q4 -

1 year ago - GlobeNewsWire

Why Earnings Season Could Be Great for 89bio (ETNB)

89bio (ETNB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 year ago - Zacks Investment Research

5 Biotech Stocks Set to Outpace Q2 Earnings Estimates

Let us take a look at some biotech stocks that are poised to beat on second-quarter earnings.

Other symbols:ARCTAVROFULCICPT
1 year ago - Zacks Investment Research

89bio to Present at Upcoming Investor Conferences

SAN FRANCISCO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the...

1 year ago - GlobeNewsWire